Cargando…
Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch
Lysine specific demethylase 1 (LSD1) is a key epigenetic eraser enzyme implicated in cancer metastases and recurrence. Nuclear LSD1 phosphorylated at serine 111 (nLSD1p) has been shown to be critical for the development of breast cancer stem cells. Here we show that circulating tumor cells isolated...
Autores principales: | Tu, Wen Juan, McCuaig, Robert D., Tan, Abel H. Y., Hardy, Kristine, Seddiki, Nabila, Ali, Sayed, Dahlstrom, Jane E., Bean, Elaine G., Dunn, Jenny, Forwood, Jade, Tsimbalyuk, Sofia, Smith, Kate, Yip, Desmond, Malik, Laeeq, Prasanna, Thiru, Milburn, Peter, Rao, Sudha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309504/ https://www.ncbi.nlm.nih.gov/pubmed/32612611 http://dx.doi.org/10.3389/fimmu.2020.01228 |
Ejemplares similares
-
A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)
por: Prasanna, Thiru, et al.
Publicado: (2022) -
Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication
por: Tu, Wen Juan, et al.
Publicado: (2021) -
Author Correction: Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication
por: Tu, Wen Juan, et al.
Publicado: (2021) -
Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8(+) T Cells in Immunotherapy-Resistant and Metastatic Cancers
por: Dunn, Jenny, et al.
Publicado: (2022) -
LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer
por: Boulding, T., et al.
Publicado: (2018)